Finance

Lists
SUPN:NASDAQ
Supernus Pharmaceuticals Inc
$42.18
-2.00%
(-0.86) 1D
$42.18
0.00% (0.00)
After hours
Closed: Oct 1, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SUPN...
Open
$43.21
High
$43.68
Low
$42.15
Mkt. cap
2.46B
Avg. vol.
618.17K
Volume
0.00
52-wk high
$59.68
52-wk low
$40.52
EPS
-$1.91
Beta
0.56
Shares outstanding
58.22M
No. of employees
778
Open
$43.21
High
$43.68
Low
$42.15
Mkt. cap
2.46B
Avg. vol.
618.17K
Volume
0.00
52-wk high
$59.68
52-wk low
$40.52
EPS
-$1.91
Beta
0.56
Shares outstanding
58.22M
No. of employees
778
News stories
From web sources and news partners
About Supernus Pharmaceuticals Inc
CEOJack A. Khattar
Employees778
Founded2005
HeadquartersRockville, Maryland, United States
SectorPharmaceutical industry
Websitesupernus.com
Analyst ratings
Based on 5 analysts giving stock ratings to SUPN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for SUPN in the last 3 months.
Highest
Current $42.18
$67.00 (+58.84%)
Average
$65.20 (+54.58%)
Lowest
$63.00 (+49.36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stacy Ku
TD Cowen
Buy
Maintained
$65.00
+54.1%
08/03/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$66.00
+56.5%
07/27/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$63.00
+49.4%
07/13/2026
Chi Meng Fong
Bank of America Securities
Buy
Maintained
$63.00
+49.4%
07/13/2026
Unknown Analyst
Jefferies
Buy
Maintained
$65.00
+54.1%
07/10/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$67.00
+58.8%
07/09/2026
Annabel Samimy
Stifel Nicolaus
Hold
Maintained
$55.00
+30.4%
05/06/2026
Pavan Patel
Bank of America Securities
Buy
Maintained
$65.00
+54.1%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
192.10M
211.57M
207.70M
219.06M
Cost of goods sold
48.33M
50.83M
62.83M
63.13M
Cost of revenue
48.33M
50.83M
62.83M
63.13M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
110.97M
124.44M
126.67M
136.04M
Operating expense
135.30M
148.96M
152.32M
161.37M
Total operating expenses
183.63M
199.80M
215.15M
224.50M
Operating income
8.48M
11.77M
-7.44M
-5.44M
Other non operating income
-
-
-
-
EBT including unusual items
-57.95M
-1.91M
-5.95M
-57.65M
EBT excluding unusual items
10.75M
14.24M
-5.06M
-5.13M
Income tax expense
-12.84M
2.19M
-3.66M
723.00K
Effective tax rate
22.15%
-114.47%
61.46%
-1.25%
Other operating expenses
-
-
-
-
Net income
-45.12M
-4.10M
-2.29M
-58.37M
Net profit margin
-23.49%
-1.94%
-1.10%
-26.65%
Earnings per share
0.61
0.88
0.21
0.53
Interest and investment income
2.28M
2.46M
2.38M
2.63M
Interest expense
-
-
-
-2.32M
Net interest expenses
2.28M
2.46M
2.38M
315.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
33.28M
36.79M
18.69M
20.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps